Method for topical treatment of herpes infections
AssigneeArthropharm PTY. Limited
InventorDavid Cullis-Hill
Life of this patent
Estimating the term…
Abstract
A method for the topical treatment of herpes virus infections of the skin and mucous membranes is disclosed- This method uses a topical preparation comprising an anti-vital drug in combination with a potentiating drug which is an anti-inflammatory or an anti-oxidant drug. A preferred preparation includes zinc pentosan polysulphate in combination with bufexamac.
Claims7
A method for the topical treatment of herpes infections in humans, comprising the step of applying to an area of skin or mucous membranes infected with herpes an effective amount of a composition which comprises a first compound which is a divalent metal ion chelate of a polysulphate of xylan having glycosidically linked D-glucuronyl side chains with divalent metal ions chelated thereto wherein the monovalent ions have been substituted by divalent ions selected from the group consisting of Ca.sup.2+, Mg.sup.2+, Cu.sup.2+ and Zn.sup.2+ in a concentration of 0.01 to about 20 weight percent, and a second compound which is a non-steroidal anti-inflammatory drug in a concentration of from about 0.01 to about 50 weight percent based on the total weight of the composition.
A method for the topical treatment of herpes infection in humans, comprising the step of applying to an area of the skin or mucous membranes infected with herpes an effective amount of a composition which comprises a divalent metal ion chelate of a polysulphate of xylan having glycosidically linked D-glucuronyl side chains with divalent metal ions chelated thereto wherein the monovalent ions have been substituted by divalent ions selected from the group consisting of Ca.sup.2+, Mg.sup.2+, Cu.sup.2+ and Zn.sup.2+ in a concentration of from 0.01 to about 20 weight percent based on the total weight of the composition, and a non-steroidal anti-inflammatory drug selected from the group consisting of diclofenac, naproxen, salicylate derivatives and bufexamac in a concentration of from about 0.01 to about 50 weight percent based on the total weight of the composition.
Dependencies are inferred from the claim text.